Candidiasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Candidiasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Candidiasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Candidiasis Therapeutics market. The report identifies the key trends shaping and driving the global Candidiasis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Candidiasis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Candidiasis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Candidiasis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Candidiasis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Candidiasis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Candidiasis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Candidiasis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Candidiasis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Candidiasis Therapeutics market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Candidiasis Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Signs and Symptoms
2.6 Diagnosis
2.7 Treatment and Management Options
2.8 GlobalData Pipeline Report Guidance
3 Candidiasis Therapeutics - Market Characterization
3.1 Candidiasis Therapeutics Market Size (2005-2010) - Global
3.2 Candidiasis Therapeutics Market Forecast (2010-2018) - Global
3.3 Candidiasis Therapeutics Market Size (2005-2010) - The US
3.4 Candidiasis Therapeutics Market Forecast (2010-2018) - The US
3.5 Candidiasis Therapeutics Market Size (2005-2010) - France
3.6 Candidiasis Therapeutics Market Forecast (2010-2018) - France
3.7 Candidiasis Therapeutics Market Size (2005-2010) - Germany
3.8 Candidiasis Therapeutics Market Forecast (2010-2018) - Germany
3.9 Candidiasis Therapeutics Market Size (2005-2010) - Italy
3.10 Candidiasis Therapeutics Market Forecast (2010-2018) - Italy
3.11 Candidiasis Therapeutics Market Size (2005-2010) - Spain
3.12 Candidiasis Therapeutics Market Forecast (2010-2018) - Spain
3.13 Candidiasis Therapeutics Market Size (2005-2010) - The UK
3.14 Candidiasis Therapeutics Market Forecast (2010-2018) - The UK
3.15 Candidiasis Therapeutics Market Size (2005-2010) - Japan
3.16 Candidiasis Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Candidiasis Therapeutics Market
3.17.1 Drivers for the Candidiasis Therapeutics Market
3.17.2 Barriers for the Candidiasis Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Candidiasis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Candidiasis Therapeutics Market - Azole Group
4.3.1 Fluconazole
4.3.2 Itraconazole
4.3.3 Clotrimazole
4.3.4 Ketoconazole
4.4 Product Profiles of the Major Marketed Products in the Candidiasis Therapeutics Market - Echinocandins Class
4.4.2 Mycamine (micafungin)
4.4.3 Nystatin (Oral Suspension)
4.5 Key Takeaway
5 Candidiasis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Candidiasis Therapeutics - Pipeline by Phases of Development
5.3.1 Candidiasis Therapeutics - Phase III Pipeline
5.3.2 Candidiasis Therapeutics - Phase II Pipeline
5.3.3 Candidiasis Therapeutics - Phase I Pipeline
5.3.4 Candidiasis Therapeutics - Pre-Clinical Pipeline
5.3.5 Candidiasis Therapeutics - Discovery Pipeline
5.3.6 Candidiasis Therapeutics - Unknown Phase Pipeline
5.3.7 Technology Trends Analytic Framework
5.4 Candidiasis Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.5 Candidiasis Therapeutics - Promising Drugs under Clinical Development
5.6 Molecules Profile for Promising Drugs under Clinical Development
5.6.1 Isavuconazole
5.7 Key Takeaway
6 Candidiasis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Candidiasis Therapeutics Clinical Trials
7 Candidiasis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Candidiasis Therapeutics - Implications for Future Market Competition
8 Candidiasis Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Basilea Pharmaceuticals
8.2.2 Astellas
8.2.3 Ferrer Internacional
8.2.4 Pacgen Biopharmaceuticals
8.2.5 NovaDigm Therapeutics
8.2.6 Pevion Biotech
8.2.7 Other Companies in the Candidiasis Therapeutics Market
9 Candidiasis Therapeutics - Licensing and Partnership Deals
10 Candidiasis Therapeutics - Appendix
10.1 Market Definitions
10.1.1 Abbreviations
10.2 Methodology
10.2.1 Coverage
10.2.2 Secondary Research
10.2.3 Forecasting
10.2.4 Primary Research
10.2.5 Expert Panel Validation
10.3 Contact Us
10.4 Disclaimer
10.5 Bibliography

1.1 List of Tables
Table 1: Common Types of Candidiasis
Table 2: Incidence Of Candidiasis
Table 3: Host Defense Mechanisms
Table 4:Therapeutic Options for Mucosal Candidiasis
Table 5: Candidiasis Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 6: Candidiasis Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 7: Candidiasis Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 8: Candidiasis Therapeutics Market, The US, Forecast ($m), 2010-2018
Table 9: Candidiasis Therapeutics Market, France, Revenue ($m), 2005-2010
Table 10: Candidiasis Therapeutics Market, France, Forecast ($m), 2010-2018
Table 11: Candidiasis Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 12: Candidiasis Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 13: Candidiasis Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 14: Candidiasis Therapeutics Market, Italian, Forecast ($m), 2010-2018
Table 15: Candidiasis Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 16: Candidiasis Therapeutics Market, Spanish, Forecast ($m), 2010-2018
Table 17: Candidiasis Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 18: Candidiasis Therapeutics Market, The UK, Forecast ($m), 2010-2018
Table 19: Candidiasis Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 20: Candidiasis Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 21: Fluconazole Clinical Study Details (for Vaginal Candidiasis)
Table 22: Fluconazole Clinical Study Details (for Immunocompromised Children with Oropharyngeal Candidiasis)
Table 23:ERAXIS Clinical Trial Details - Efficacy Analysis: Global Success in Patients with Candidemia and other Candida infections (MITT Population)
Table 24: ERAXIS Clinical Trial Details - Endoscopy Results in Patients with Esophageal Candidiasis (Clinically Evaluable Population) - Endoscopic Response at End of Therapy
Table 25: Micafungin (Mycamine) Clinical Trial Details - Efficacy Analysis: Treatment Success in Patients in Study 03-0-192 with Candidemia and Other Candida Infections
Table 26: Micafungin (Mycamine) Clinical Trial Details - Endoscopic, Clinical and Mycological Outcomes for Esophageal Candidiasis at End of Treatment
Table 27: Micafungin (Mycamine) Clinical Trial Details - Relapse of Esophageal Candidiasis at Week Two and through Week Four Post-Treatment in Patients with Overall Therapeutic Cure at End of Treatment
Table 28: Major Marketed Products Comparison in the Candidiasis Therapeutics Market
Table 29: Candidiasis Therapeutics - Phase III Pipeline, 2011
Table 30: Candidiasis Therapeutics - Phase II Pipeline, 2011
Table 31: Candidiasis Therapeutics - Phase I Pipeline, 2011
Table 32: Candidiasis Therapeutics - Pre-Clinical Pipeline, 2011
Table 33: Candidiasis Therapeutics - Discovery Pipeline, 2011
Table 34: Candidiasis Therapeutics - Unknown Pipeline, 2011
Table 35: Candidiasis Therapeutics - Most Promising Drugs under Clinical Development, 2011
Table 36: Candidiasis Therapeutics - Clinical Trials by Region/Country, 2011
Table 37: Candidiasis Therapeutics - Clinical Trials by Phase, 2011
Table 38: Candidiasis Therapeutics - Clinical Trials by Status, 2011
Table 39: Candidiasis Therapeutics - Overall Sponsors, 2011
Table 40: Candidiasis Therapeutics - Prominent Sponsors, 2011
Table 41: Candidiasis Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 42: Basilea Pharmaceuticals - Infectious Disease, Pipeline, 2011
Table 43: Astellas Pharma - Infectious Disease, Pipeline, 2011
Table 44: Pacgen Biopharmaceuticals - Infectious Disease, Pipeline, 2011
Table 45: NovaDigm Therapeutics - Infectious Disease , Pipeline, 2011
Table 46: Pevion Biotech - Infectious Disease, Pipeline, 2011
Table 47: Candidiasis Therapeutics - Future Players
Table 48: Candidiasis Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Candidiasis Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 2: Candidiasis Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 3: Candidiasis Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 4: Candidiasis Therapeutics Market, The US, Forecast ($m), 2010-2018
Figure 5: Candidiasis Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 6: Candidiasis Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 7: Candidiasis Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 8: Candidiasis Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 9: Candidiasis Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 10: Candidiasis Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 11: Candidiasis Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 12: Candidiasis Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 13: Candidiasis Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 14: Candidiasis Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 15: Candidiasis Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 16: Candidiasis Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 17: Opportunity and Unmet Need in the Oropharyngeal Candidiasis Therapeutics Market
Figure 18: Opportunity and Unmet Need in the Esophageal Candidiasis Therapeutics Market
Figure 19: Opportunity and Unmet Need in the Systemic Candidiasis Therapeutics Market
Figure 20: Opportunity and Unmet Need in the Vaginal Candidiasis Therapeutics Market
Figure 21: Oropharyngeal Candidiasis Therapeutics - Strategic Competitor Assessment, 2011
Figure 22: Esophageal Candidiasis Therapeutics - Strategic Competitor Assessment, 2011
Figure 23: Systemic Candidiasis Therapeutics - Strategic Competitor Assessment, 2011
Figure 24: Vaginal Candidiasis Therapeutics - Strategic Competitor Assessment, 2011
Figure 25: Candidiasis Therapeutics - Pipeline by Phase of Development, 2011
Figure 26: Candidiasis Therapeutics - Technology Trends Analytics Framework, 2011
Figure 27: Candidiasis Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 28: Candidiasis Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 29: Candidiasis Therapeutics - Clinical Trials by Region/Country, 2011
Figure 30: Candidiasis Therapeutics - Clinical Trials by Phase, 2011
Figure 31: Candidiasis Therapeutics - Clinical Trials by Status, 2011
Figure 32: Candidiasis Therapeutics - Overall Sponsors, 2011
Figure 33: Candidiasis Therapeutics - Prominent Sponsors, 2011
Figure 34: Candidiasis Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 35: Candidiasis Therapeutics Market - Drivers and Barriers 2011
Figure 36: Implications for Future Market Competition in the Candidiasis Therapeutic Market, 2011
Figure 37: Candidiasis Therapeutics Market - Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Candidiasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global candidiasis therapeutics market. The report identifies the key trends shaping and driving the global candidiasis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global candidiasis therapeutics market sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Candidiasis Therapeutics Market is Forecast to Show Moderate Growth until 2018

GlobalData’s analysis shows that the global candidiasis therapeutics market was worth $1,992.7m in 2005 and grew at Compound Annual Growth Rate (CAGR) of 11.8% to $3,476.9m in 2010. GlobalData forecasts that the market will grow at a CAGR of 5.6% to reach $5,388.9m by 2018. The current competitive landscape consists of azoles, echinocandins and polyenes. The azoles class comprises products such as fluconazole, itraconazole, clotrimazole, voriconazole, ketoconazole and posoconazole. Most of the drugs in the azoles class are generics, and the only branded product is posoconazole, under the brand name Noxafil. The drugs in the polyenes class are also generics. The only class which consists entirely of branded products is echinocandins, namely ERAXIS (anidulafungin), Mycamine (micafungin) and Cancidas (caspofungin).

The moderate market growth is attributed to the fact that the market is dominated by generic products and has a weak pipeline with only one company-sponsored first-in-class molecule (isavuconazole) in the late stage of development.

The forecast growth can be attributed to the increase in the candidiasis patient population due to the increasing number of immunocompromised patients.

Candidiasis Therapeutics Market, Global, Revenue and Forecast ($m), 2005-2018

Source: GlobalData, Centre for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases, Jose A Hidalgo, MD; Chief Editor: Burke A Cunha, MD,Candidiasis,2010,Published in Medscape, M. A. Pfaller, D. J. Diekema, Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem,2007,Published by American Society for Microbiology, GlobalData Epidemiology-based market Forecasting Model

Basilea Pharmaceuticals
Astellas
Ferrer Internacional
Pacgen Biopharmaceuticals
NovaDigm Therapeutics
Pevion Biotech